The retinoblastoma paradigm revisited

Medical Science Monitor

Volumn 14, Issue 12, 2008, Pages

  Mastrangelo, Domenico ^a   De Francesco, Sonia ^a   Di Leonardo, Aldo ^b   Lentini, Laura ^b   Hadjistilianou, Theodora ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b Department of Cell and Developmental Biology A Monroy Palermo ^*  (Italy)

Author keywords

"Two hit" theory; Aneuploidy; Cancer genetics; Epigenetics; Gene mutations; Retinoblastoma

Indexed keywords

ANEUPLOIDY; CANCER GENETICS; CHILDHOOD CANCER; DISEASE ASSOCIATION; DNA TUMOR VIRUS; EPIGENETICS; FAMILIAL CANCER; GENE MUTATION; HUMAN; INTRAOCULAR TUMOR; NONHUMAN; ONSET AGE; PATHOGENESIS; RETINOBLASTOMA; REVIEW; SYSTEMATIC REVIEW; TUMOR DIAGNOSIS; TUMOR SUPPRESSOR GENE; WART VIRUS;

AGE FACTORS; HUMANS; INFANT; MUTATION; RETINOBLASTOMA;

EID: 57349196431     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Karcioglu ZA, Hadjistilianou T: Ocular tumors. In: Karcioglu ZA, ed. Orbital tumors - diagnosis and treatment. New York: Springer, 2004. 257-65
2. Shields CL, Meadows AT, Leahey AM, Shields JA: Continuing challenges in the management of Rb with chemotherapy. Retina, 2004; 24(6): 849-62
3. Knudson AG: Mutation and cancer: statistical study of Rb. Proc Nat Acad Sci USA, 1971; 68(4): 820-23
4. Knudson AG Jr: Heredity and human cancer. Am J Pathol, 1974; 77: 1. 77-84
5. Knudson AG: The genetics of childhood cancer. Cancer, 1975; 3(Suppl.): 1022-26
6. Knudson AG: Genetics of human cancer. Genetics, 1975; 79(Suppl.): 305-16
7. Knudson AG: Mutation and childhood cancer: a probabilistic model for the incidence of Rb. Proc Natl Acad Sci, 1975; 72(12): 5116-20
8. Knudson AG: Mutation and cancer in man. Cancer, 1977; 39(Suppl.4): 1882-86
9. Knudson AG: Model for the incidence of embryonal cancers: application to Rb. Proc Natl Acad Sci, 1978; 75(5): 2453-57
10. Knudson AG: Hereditary cancer. JAMA, 1979; 241(3): 279
11. Knudson AG: Persons at high risk of cancer. N Engl J Med, 1979; 301(11): 606-7
12. Knudson AG: Genetics and cancer. Am J Med, 1980; 69(1): 1-3
13. Knudson AG: Hereditary cancer, oncogenes, and antioncogenes. Cancer Res, 1985; 45(4): 1437-43
14. Knudson AG: Hereditary cancers disclose a class of cancer genes. Cancer, 1989; 63(10): 1888-91
15. Knudson AG: Antioncogenes and human cancer. Proc Natl Acad Sci, 1993; 90(23): 10914-21
16. Knudson AG: Hereditary cancers: from discovery to intervention. J Natl Cancer Inst Monogr, 1995; 17: 5-7
17. Knudson AG: Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol, 1996; 122(3): 135-40
18. Knudson AG: Cancer genetics. Am J Med Genet, 2002; 111(1): 96-102
19. Knudson AG: Cancer genetics through a personal retrospectroscope. Genes Chromosomes Cancer, 2003; 38(4): 288-91
20. Knudson AG: Of sea urchins and worms: development and cancer. Cell Death Differ, 2004; 11(1): 11-12
21. Knudson AG: A personal sixty-year tour of genetics and medicine. Ann Rev Gen Hum Genet, 2005; [Epub ahead of print]; http://www.cancerindex.org/ geneweb/RB1.htm#t51
22. Kiss S, Leiderman YI, Mukai S: Diagnosis, classification, and treatment of Rb. Int Ophthalmol Clin, 2008; 48(2): 135-47
23. Chintagumpala M, Chevez-Brrios P, Paysse E et al: Review of Current Management. The Oncologist, 2007; 12: 1237-46
24. http://www.geneclinics.org/profiles/Rb/details.html
25. Mastrangelo D, Acquaviva A, Di Pisa F et al: Italian register for Rb. Pros and cons of a retrospective statistical study. Ophthalmic Paediatr Genet, 1991; 12(2): 73-78
26. Mastrangelo D, De Francesco S, Di Leonardo A et al: Does the evidence matter in medicine? The Rb paradigm. Int J Cancer, 2007; 121(11): 2501-5
27. Mastrangelo D, De Francesco S, Di Leonardo A et al: Rb epidemiology: does the evidence matter? Eur J Cancer, 2007; 43(10): 1596-603
28. http://www.ruf.rice.edu/~lane/stat_sim/descriptive/index.html
29. Shields JA, Shields CL: Genetics of Rb. In: Shields JA, Shields CL, eds. Intraocular Tumors: A Text and Atlas. Philadelphia, Pa: WB Saunders, 1992; 333-40
30. Shields CL, Shields JA: Diagnosis and management of Rb. Cancer Control, 2004; 11(5): 317-27
31. Chen D, Livne-Bar I, Vanderluit JL et al: Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically deathresistant cell-of-origin in Rb. Cancer Cell, 2004; 5: 539-51
32. MacPherson D, Sage J, Kim T et al: Cell type-specific effects of Rb deletion in the murine retina. Genes Dev, 2004; 18: 1681-94
33. Zhang J, Gray J, Wu L et al: Rb regulates proliferation and rod photoreceptor development in the mouse retina. Nat Genet, 2004; 36: 351-60
34. Donovan SL, Schweers B, Martins R et al: Compensation by tumor suppressor genes during retinal development in mice and humans. BMC Biol, 2006; 4: 14
35. Brinkert AW, Moll AC, Jager MJ et al: Distribution of tumors in the retina in hereditary Rb patients. Ophthalmic Genet, 1998; 19(2): 63-67
36. Ajioka I, Martins RAP, Bayazitov IT et al: Differentiated Horizontal Interneurons Clonally Expand to Form Metastatic Rb in Mice Cell, 2007; 131(2): 378-90
37. te Riele H: Rb teaches a new lesson. Cell, 2007; 131(2): 227-29
38. Madhavan J, Ganesh A, Roy J et al: The relationship between tumor cell differentiation and age at diagnosis in Rb. J Pediatr Ophthalmol Strabismus, 2008; 45(1): 22-25
39. Stiller C, Parkin D: Geographic and ethnic variations in the incidence of childhood cancer. Br Med Bull, 1996; 52: 682-703
40. Stiller CA: Epidemiology and genetics of childhood cancer. Oncogene, 2004; 23(38): 6429-44
41. Orjuela MA, Titievsky L, Liu X et al: Fruit and vegetable intake during pregnancy and risk for development of sporadic Rb. Cancer Epidemiol Biomarkers Prev, 2005; 14(6): 1433-40
42. Orjuela M, Castaneda VP, Ridaura C et al: Presence of human papilloma virus in tumor tissue from children with Rb: An alternative mechanism for tumor development. Clin Cancer Res, 2000; 6: 4010-16
43. Strati K, Lambert PF: Role of Rb-dependent and Rb-independent functions of papillomavirus E7 oncogene in head and neck cancer. Cancer Res, 2007; 67(24): 11585-93
44. Wise-Draper TM, Wells SI: Papillomavirus E6 and E7 proteins and their cellular targets. Front Biosci, 2008; 13: 1003-17
45. Gillison ML, Chen R, Goshu E et al: Human Rb is not caused by known pRb-inactivating human DNA tumor viruses. Int J Cancer, 2007; 120(7): 1482-90
46. Iovino F, Lentini L, Amato A, Di Leonardo A: RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. Mol Cancer, 2006; 5: 38
47. Wentzensen N, Vinokurova S, Doeberitz MvK: Systematic Review of Genomic Integration Sites of Human Papillomavirus Genomes in Epithelial Dysplasia and Invasive Cancer of the Female Lower Genital Tract. Cancer Research, 2004; 64, 3878-84
48. Hume AJ, Finkel JS, Kamil JP et al: Phosphorylation of Rb protein by viral protein with cyclin-dependent kinase function. Science, 2008; 320(5877): 797-99
49. Blanquet V, Turleau C, Gross-Morand MS et al: Spectrum of germline mutations in the RB1 gene: a study of 232 patients with hereditary and non hereditary Rb. Hum Mol Genet, 1995; 4(3): 383-88
50. Houdayer C, Dehainault C, Mattler C et al: Evaluation of in silico splice tools for decision-making in molecular diagnosis. Hum Mutat, 2008
51. Houdayer C, Gauthier-Villars M, LaugeA et al: Comprehensive screening for constitutional RB1 mutations by DHPLC and QMPSF. Hum Mutat, 2004; 23: 193-202
52. http://www.cancerindex.org/geneweb//RB1.htm
53. Valverde JR, Alonso J, Palacios I, Pestaña A: RB1 gene mutation up-date, a meta-analysis based on 932 reported mutations available in a searchable database. BMC Genetics, 2005, 6: 53, http://www.biomedcentral.com/ 1471-2156/6/53
54. http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijovs/ vol1n2/gene.xml
55. Jirtle RL, Skinner MK: Environmental epigenomics and disease susceptibility. Nature Reviews Genetics, 2007; 8: 252-62
56. Dolinoy DC, Jirtle RL: Environmental epigenomics in human health and disease. Environ Mol Mutagen, 2008; 49(1): 4-8
57. http://www.infobiogen.fr/services/chromcancer/Genes/RB1ID90.html
58. Fan BJ, Tam PO, Choy KW et al: Molecular diagnostics of genetic eye diseases. Clin Biochem, 2006; 39(3): 231-39
59. Richter S, Vandezande K, Chen N et al: Sensitive and efficient detection of RB1 gene mutations enhances care for families with Rb. Am J Hum Genet, 2003; 72(2): 253-69
60. http://www.Rbsolutions.org/testsent.html
61. Nichols KE, Houseknecht MD, Godmilow et al: Multistep clinical molecular screening of 180 unrelated individuals with Rb detects 36 novel mutations in the RB1 gene. Hum Mutat, 2005; 6: 566-74
62. http://www.cancerindex.org/geneweb/RB1.htm#t51
63. Bellan C, De Falco G, Tosi GM et al: Missing expression of pRb2/p130 in human Rbs is associated with reduced apoptosis and lesser differentiation invest. Ophthalmol Vis Sci, 2002; 43: 3602-8
64. Harada K, Toyooka S, Maitra A et al: Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene, 2002; 21(27): 4345-49
65. Harada K, Toyooka S, Shivapurkar N et al: Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines. Cancer Res, 2002; 62(20): 5897-901
66. Rathi A, Virmani AK, Harada K et al: Aberrant methylation of the HIC1 promoter is a frequent event in specific pediatric neoplasms. Clin Cancer Res, 2003; 9(10 Pt 1): 3674-78
67. Shigematsu H, Suzuki M, Takahashi T et al: Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies. Int J Cancer, 2005; 113(4): 600-4
68. Laurie NA, Donovan SL, Shih CS et al: Inactivation of the p53 pathway in retinoblastoma. Nature, 2006; 444(7115): 45-46
69. Laurie NA, Schin-Shih C, Dyer MA: Targeting MDM2 and MDMX in retinoblastoma. Curr Cancer Drug Targets, 2007; 7(7): 689-95
70. Wallace VA: Cancer biology: Second step to retinal tumours. Nature, 2006; 444: 45-46
71. Li R, Sonik A, Rasnik D, Duesberg P: Aneuploidy vs. gene mutation hypothesis of cancer: Recent studies claims mutation but is found to support aneuploidy. Proc Natl Acad Sci, 2000; 97(7): 3236-41
72. Duesberg P, Li R, Rasnick D: Aneuploidy approaching a perfect score in predicting and preventing cancer. Cell Cycle, 2004; 3: 823-28
73. Duesberg PH: Are cancers dependent on oncogenes or on aneuploidy? Cancer Genet Cytogent, 2003; 143: 89-91
74. Fabarius A, Hehlmann R, Duesberg PH: Instability of chromosome structure in cancer cells increases exponentially with degrees of aneuploidy. Cancer Genet Cytogenet, 2003; 143: 59-72
75. Li R, Rasnick D, Duesberg P: Correspondence re: D Zimonjic et al. Derivation of human tumor cells in vitro without widespread genomic instability. Cancer Res, 2001; 61: 8838-44, Cancer Res 2002; 62: 6345-48, author reply 6348-49
76. Fabarius A, Willer A, Yerganian G et al: Specific aneusomies in Chinese hamster cells at different stages of neoplastic transformation, initiated by nitrosomethylurea. Proc Natl Acad Sci, 2002; 99: 6778-83
77. Duesberg P, Stindl R, Li RH et al: Aneuploidy versus gene mutation as cause of cancer. Curr Sci, 2001; 81: 490-500
78. Duesberg P, Li R, Fabarius A, Hehlmann R: The chromosomal basis of cancer. Cellular Oncology, 2005; 27: 293-318
79. Duesberg P, Li R: Multistep carcinogenesis: a chain reaction of aneuploidizations. Cell Cycle, 2003; 2: 202-10
80. Duesberg P: Does aneuploidy or mutation start cancer? Science, 2004; 307(5706): 41
81. Rasnick D, Duesberg PH: How aneuploidy affects metabolic control and causes cancer. Biochem J, 1999; 340: 621-30
82. Duesberg P, Li R, Rasnick D et al: Aneuploidy precedes, and segregates with chemical carcinogenesis. Cancer Genet Cytogenet, 2000; 119: 83-93
83. Hede K: Which came first? Studies clarify role of aneuploidy in cancer. J Natl Cancer Inst, 2005; 97(2): 87-89
84. Lentini L, Pipitone L, Di Leonardo A: Functional inactivation of pRB results in aneuploid mammalian cells after release from a mitotic block. Neoplasia, 2002; 4(5): 380-87
85. Hernando E, Nahle Z, Juan G et al: Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature, 2004; 430(7001): 797-802
86. Matsumoto Y, Hayashi K: Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells. Curr Biol, 1999; 8: 429-32
87. Meraldi P, Lukas J, Fry AM et al: Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A. Nat Cell Biol, 1999; 2: 88-93
88. Doxsey S, Zimmerman W, Mikule K: Centrosome control of the cell cycle. Trends Cell Biol, 2005; 6: 303-11
89. Iovino F, Lentini L, Amato A, Di Leonardo A: RB acute loss induces centrosome amplification and aneuploidy in murine primary fibroblasts. Mol Cancer, 2006; 5: 38
90. Duensing S, Duensing A, Lee DC et al: Cyclin-dependent kinase inhibitor indirubin-30-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene, 2004; 23(50): 8206-15
91. http://ghr.nlm.nih.gov/condition=Rb
92. http://www.ncbi.nlm.nih.gov/sites/entrez
93. Corson TW, Gallie BL: One hit, two hits, three hits, more? Genomic changes in the development of Rb. Genes Chromosomes Cancer, 2007; 46(7): 617-34
94. Joseph B, Kumaramanickavel B: 'Insight' into Molecular Genetic Testing in Rb Int J Hum Genet, 2007; 7(1): 23-28
95. Gallie BL: Predictive Testing for Rb Comes of Age. Am J Hum Genet, 1997; 61: 279-81
96. Richter S, Vandezande K, Chen N et al: Sensitive and efficient detection of RB1 gene mutations enhances care for families with Rb. Am J Hum Genet, 2003; 72(2): 253-69
97. Gallie BL, Zhao J, Vandezande K et al: Global issues and opportunities for optimized Rb care. Pediatr Blood Cancer, 2007; 49(Suppl.7): 1083-90
98. Rao A, Rothman J, Nichols KE: Genetic testing and tumor surveillance for children with cancer predisposition syndromes. Curr Opin Pediatr, 2008; 20(1): 1-7
99. http://www.accessexcellence.org/AE/AEPC/NIH/gene16.php
100. American Society for Clinical Oncology: American Society of Clinical Oncology Policy Statement Update: Genetic Testing for Cancer Susceptibility. J Clin Oncol, 2003; 21(12): 1-10
101. Jubran RF, Villablanca JG, Meadows AT: Chemotherapy for Rb: am overview. In: Singh A, D'Amato B, Pe'er J, Murphree L, Perry J: Clinical Ophthalmic Oncology Saunders - Elsevier, 2007; 449-53
102. Murphree L: Local therapy, brachytherapy and enucleation. In: Singh A, D'Amato B, Pe'er J, Murphree L, Perry J: Clinical Ophthalmic Oncology Saunders - Elsevier, 2007; 454-61
103. Merchant TE: Teletherapy: indications, risks, and new delivery options. In: Singh A, D'Amato B, Pe'er J, Murphree L, Perry J: Clinical Ophthalmic Oncology Saunders - Elsevier, 2007; 462-67
104. http://www.orpha.net/consor/cgi-bin/index.php?lng=EN
105. http://www.virusmyth.net/aids/data/drstate.htm